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Transfection of the E6 gene of human papillovirus (HPV) 16 into primary human keratinocytes (PHKs) generates proliferating cell
colonies which are resistant to serum- and calcium-induced terminal differentiation. The extreme C-terminus of E6 was shown to
be dispensable for this activity. To map further the amino acid sequences required for inducing resistance to serum and calcium,
and to address the functional significance of E6 interactions with p53 and E6BP (ERC-55) in this function, we evaluated the
activities of a series of E6 mutants. Small deletions within the central portion of the second putative zinc-finger abolished, or
markedly reduced, E6 biological activity, while mutations affecting the cysteine residues in the base of the finger were less effective
in this respect. When these mutants were assayed for their ability to degrade p53 in vitro and in vivo and to inhibit p53
transcriptional activation (TA), we found that there was a dissociation of these activities in some mutants. We mapped one mutant
which was highly efficient in p53 degradation and inhibition of p53 TA, yet displayed severely reduced activity in the biological
assay, and conversely, a subset of mutants that showed moderate activities in the colony assay while being severely impaired in
p53 degradation and inhibition of p53 TA. These data argue that p53 inactivation or even elimination are not sufficient, and may
not be essential, for altering the response of PHKs to serum and calcium. When these E6 mutants were evaluated for E6BP binding
in vitro, there was a similar dissociation between the biological and biochemical activities of several mutants. We mapped mutants
with moderate activity in the biological assay that lacked the ability to bind to E6BP and a mutant that showed high biological
activity with only marginal binding to E6BP. Thus, there is no absolute correlation between the ability of E6 mutant proteins to
induce alterations in keratinocyte differentiation responses to calcium and serum and to induce p53 degradation, inhibit p53
mediated transactivation, or bind E6BP. Evidently there are additional cellular targets for E6 which mediate this alteration in cellular
differentiation. © 2002 Elsevier ScienceINTRODUCTION
The major etiological agents of cervical cancer are
human papillomaviruses (HPV) (for review, see Zur-
Hausen, 1996, 2000). Infection of the basal epithelium of
the anogenital mucosa with HPV types referred to as
“high risk” or oncogenic perturbs squamous cell differ-
entiation and enhances cell proliferation. Two oncopro-
teins are encoded by the oncogenic HPVs, E6 and E7. In
vitro studies have shown that these proteins cooperate
to immortalize primary human genital keratinocytes
(PHKs) (Schlegel et al., 1988; Hawley-Nelson et al., 1989),
they alter the differentiated phenotype of keratinocytes
(Hudson et al., 1990; Halbert et al., 1992; Woodworth et
al., 1992), and they inhibit keratinocyte terminal differen-
tiation induced by serum and calcium (Schlegel et al.,
1988; Munger et al., 1989). In transgenic mice both E6
and E7 cause skin tumors. It is the E6 protein that
contributes most significantly to their malignant conver-1 To whom correspondence and reprint requests should be ad-
dressed. Fax: 972-3-6409160. E-mail: lsherman@post.tau.ac.il.
309sion (Song et al., 1999). E6 and E7 exert the transforming
activities, at least in part, through their ability to interact
with cellular tumor suppressor proteins and inactivate
their function. E7 primarily associates with cell-cycle
regulatory proteins that control cell-cycle progression
(for review, see Zwerschke and Jansen-Durr, 2000),
whereas E6 oncoprotein primarily associates with pro-
teins participating in the control of genome stability or
signaling pathways that involve cell–cell interactions and
cytoskeleton organization (for review, see Kubbutat and
Vousden, 1998; Rapp and Chen, 1998; Thomas et al., 1999).
The roles of the individual viral proteins in altering
epidermal differentiation and mechanism(s) of activity
are not completely understood, particularly since differ-
ent epithelial differentiation systems have been used to
study the responses to the viral oncoproteins. In the raft
culture system, as a model for reproducing the three-
dimensional structure of the skin, expression of E7 alone
had a limited effect on morphological differentiation
(Hudson et al., 1990; Blanton et al., 1992; Cheng et al.,
1995), although E7, but not E6, was capable of reactivat-
ing cellular DNA synthesis in the suprabasal differenti-
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310 SHERMAN ET AL.ated keratinocytes (Blanton et al., 1992; Halbert et al.,
1992; Cheng et al., 1995). In PHKs induced to differentiate
by elevation of calcium, HPV16 E7 was shown to delay
differentiation through its ability to bind and alter the
activity of cyclin/CDK inhibitor, p21 (Jones et al., 1997).
Using organotypic raft cultures of immortalized human
keratinocytes that support productive replication of
HPV16 episomes, perturbation of the normal program of
keratinocyte differentiation was shown to be dependent
on an intact E7 gene (Flores et al., 2000). In transgenic
mice E6 inhibited epithelial differentiation and induced
epithelial cell hyperplasia (Song et al., 1999). In PHKs
induced to differentiate in vitro by serum and calcium E6
increased the survival of differentiating keratinocytes (Al-
fandari et al., 1999). Using a quantitative keratinocyte
transformation assay that scores for resistance to se-
rum- and calcium-triggered differentiation, we showed
previously that HPV16 E6 protein by itself is capable of
inducing colonies of live cells to become resistant to
terminal differentiation (Sherman and Schlegel, 1996).
Differentiation resistance induced by E6 was found to be
different from keratinocyte immortalization, which re-
quired the combined presence of E7. The cellular targets
involved in E6 function in calcium and serum resistance
are not known.
E6 proteins of the high risk HPVs physically interact
with a plethora of cellular proteins (for review, see Kub-
butat and Vousden, 1998; Rapp and Chen, 1998; Thomas
et al., 1999). p53 was the first target to be shown. HPV E6
binds to p53 via the E6AP protein, a ubiquitin ligase, and
induces p53 degradation through the ubiquitin pathway
(Scheffner et al., 1990; Huibregtse et al., 1991, 1993). E6
binding to p53 was also shown to interfere with p53/DNA
binding and consequently with p53 transcriptional activ-
ity (Lechner et al., 1992; Thomas et al., 1995). Recent
studies provided evidence that E6 can inhibit p53 tran-
scriptional activity by a competitive binding to the CBP or
p300 transcriptional coactivators (Patel et al., 1999; Zim-
mermann et al., 1999). The role of p53 in the control of
keratinocyte proliferation and differentiation is not clear
(Gandarillas, 2000). Loss of p53 function has been
shown to be essential in immortalization of primary hu-
man keratinocytes in conjunction with E7 (Sedman et al.,
1992) and in immortalization of primary mammary epi-
thelial cells (MEC) (Dalal et al., 1996; Gao et al., 1996),
although other functions of E6 apparently also contribute
to E6 induced immortalization (Sedman et al., 1992; Liu et
al., 1999), including the activation of telomerase (Klin-
gelhutz et al., 1996; Kiyono et al., 1998).
Other protein targets of HPV E6 that were described
include the E6 binding protein, E6BP, a putative calcium
binding protein (Chen et al., 1995); paxillin, a focal adhe-
sion protein (Tong and Howley, 1997); the human homo-
logue of the Drosophila discs large tumor suppressor
protein (hDlg) (Kiyono et al., 1997; Lee et al., 1997);
interferon regulatory factor-3 (Ronco et al., 1998); multi-copy maintenance protein 7, a subunit of the replication
licensing factor-M (Kuhne and Banks, 1998); the pro-
apoptotic protein Bak (Thomas and Banks, 1998); c-Myc
oncogene (Gross-Mesilaty et al., 1998); E6TP1, a putative
GAP protein (Gao et al., 1999); the newly identified pro-
tein kinase (PKN) that phosphorylates E6 (Gao et al.,
2000); and the multi-PDZ domain proteins MUPP1 (Lee et
al., 2000), MAGI-1 (Glaunsinger et al., 2000), and Scribble
(Nakagawa and Huibregtse, 2000). The significance of
these interactions for E6 transformation functions have
yet to be determined, although E6 binding to hDlg, IFR3,
and E6BP appear not to be required for E6 immortaliza-
tion of cells (Kiyono et al., 1998; Ronco et al., 1998; Liu et
al., 1999).
In previous studies using a set of HPV16 E6 truncation
mutants, we mapped the domain between amino acids
residues 132–141 as being essential for the induction of
resistance to calcium- and serum-triggered differentia-
tion (Sherman and Schlegel, 1996). Further investigation
of the activities of these mutants in p53 degradation and
inhibition p53-dependent transactivation showed a cor-
relation between E6 biological activity in resistance to
terminal differentiation and activity in the above assays,
implying the importance of p53 in this cellular process.
However, investigation of MDM-2 and a transdominant
p53 mutant showed that expression of these p53 inhib-
itory proteins in PHKs could not substitute for E6 in the
colony formation assay, suggesting that activities other
than p53 inactivation are also involved (Sherman et al.,
1997). In the present study we wished to further define
the E6 protein sequences required for the induction of
serum–calcium resistant colonies in PHKs and to estab-
lish the requirement of E6 interactions with p53 in this E6
biological function. We also addressed the biological
relevance of E6BP. E6BP, also called ERC-55, appeared
to be an intriguing candidate since it is a member of
cellular calcium binding proteins that are involved in
signaling pathways of cell growth and differentiation
(Donato, 1999; Honore and Vorum, 2000).
For this purpose, previously described mutants (Crook
et al., 1991) carrying small deletions and point mutations
within the carboxyl half of E6 were recloned to include
the AU1 epitope at the C-terminus. The resulting mutants
were analyzed for their biological activities in formation
of differentiation-resistant colonies in PHKs and bio-
chemical activities in p53 degradation in vitro and in vivo,
inhibition of p53-dependent transactivation, and in vitro
binding of E6BP.
RESULTS
Activity of HPV16 E6 carboxy-terminal mutants in the
induction of calcium- and serum-resistant colonies in
PHKsPrevious analyses of a series of epitope-tagged E6
C-terminal truncation mutants indicated the requirement
311HPV 16 E6 MUTATIONAL ANALYSISfor amino acids 132–141 for the formation of colonies
resistant to calcium- and serum-induced terminal differ-
entiation in PHKs (Sherman and Schlegel, 1996). To fur-
ther map the amino acid sequences required for this E6
function, a series of previously described mutants carry-
ing small deletions and amino acid substitutions within
the central and carboxyl half of E6 (Crook et al., 1991)
were evaluated in this assay. Intact DNAs of the respec-
tive mutants were amplified by PCR to append the AU1
epitope tag at the carboxy-terminus end and recloned
into the pJS55 vector in the same context as that of the
full-length E6A (Sherman and Schlegel, 1996) (Fig. 1). The
abilities of the mutants to express detectable proteins,
capable of nuclear localization, were verified by trans-
fection into COS cells and detection of the proteins by
immunofluorescence staining and immunoprecipitation
with the AU1 antibody. The majority of the mutants
showed significant levels of expression comparable to
FIG. 1. Schematic representation of deletion and point mutation
HPV16 E6 mutants containing the AU1 tag at the C-terminal end.
Previously described mutants (Crook et al., 1991) were tagged and
recloned into pJS 55 as described under Materials and Methods. The
original names of the clones describing the positions of the amino acid
deletions or substitutions and numbers of the pTZ original clones
(Crook et al., 1991) are shown.that of E6A. Mutant 225 (Gly 136) showed somewhat
reduced expression as reflected in the relative bandintensities and number of immunofluorescent cells. Mu-
tant 1383 (d106–110) was detected by immunoprecipita-
tion after long exposure of the gel (data not shown).
Colony formation assays were carried out by cotransfec-
tion of 10 mg of the E6A mutant DNA with 10 mg of the E7
expression plasmid. E7 was included to ensure that lack
of activity of an E6 mutant is not due to a function that
can be complemented by E7. Transfection of E7 by itself
did not induce colonies in PHKs (Sherman and Schlegel,
1996 and data not shown from the present study).
Results of these assays are presented in Table 1. None
of the mutants analyzed exhibited biological ability com-
parable to that of the full-length E6A control, as reflected
in the number of experiments yielding colonies and the
average number of colonies formed. Mutations affecting
the cysteine residues at positions 136, 106, and 103,
including point mutations and small deletions, did not
abolish E6 ability to induce colonies in PHKs, although it
reduced mutant activities to a different extent. Mutant
225 (Gly 136) was the least to be affected, as indicated by
its substantial activity in high proportion of the colony
assays in PHKs and the relative number of colonies.
Deletion mutants 599 (d133–137), 1383 (d106–110), and
605 (d101–105) that lack the cysteine residues at posi-
tions 136, 106, and 103, respectively, showed moderate
activities in the colony assays, while mutant 229 (Gly103)
was significantly impaired.
Small deletions within the loop region of the second
putative zinc-finger either completely abrogated biologi-
cal activity (mutants 600 (d128–132), 601 (d123–127), 603
(d111–115)), or greatly reduced activity, as indicated by
mutant 602 (d118–122). Mutant 609, which contains a
small deletion in the hinge region between the N- and
C-terminal putative zinc-fingers, showed partial activity in
the colony assays. Results of these analyses imply that
sequences located in the central portion of the second
zinc-finger are essential for the calcium–serum resis-
tance function of E6.
Ability of E6 mutant proteins to target p53 for
degradation in vitro and in vivo
Previous studies that were based on a limited number
of E6 truncation mutants (Sherman et al., 1997) and
naturally occurring E6 variants (Conrad Stoppler et al.,
1996) showed a good correlation between the ability of
E6 to target p53 for degradation in vitro and to induce
differentiation-resistant keratinocyte colonies. To further
investigate the requirement of p53 degradation for inhi-
bition of PHK differentiation, we analyzed the activities of
the additional E6 mutants described above in p53 deg-
radation assay (Table 1).
Although the intact forms of most of these mutants
have been previously characterized for p53 binding and
degradation (Crook et al., 1991, 1994; Foster et al., 1994;
e calcu
312 SHERMAN ET AL.Liu et al., 1999), their activities were evaluated following
addition of the AU1 epitope.
Mutants were assessed for their ability to induce p53
degradation in vitro, in a standard degradation assay
with 35S-labeled p53 and E6 proteins, and in vivo, in
transient transfection assays using the p53 null Saos
cells. Mutants were evaluated for their activities in both
these assays since previous studies indicated that E6
activities could vary depending on whether in vitro and in
vivo degradation assays were utilized (Liu et al., 1999).
In the in vitro assay, E6A mutant proteins translated in
WGE were mixed with p53 translated in RTL and incu-
bated at 25°C for 3 h. Levels of p53 remaining in the
reaction were determined by SDS–PAGE analysis (Fig.
2). The extent of p53 degradation was quantified by
densitometric scanning of the p53 bands. The average
degradation activities of the various E6 proteins, relative
to E6A, obtained from multiple independent assays were
presented in Table 1. Degradation assays in which the
amounts of the mutant proteins were increased up to
threefold did not change the results (data not shown).
In the in vivo assays, E6A/mutant plasmid DNA was
cotransfected with the p53 expression plasmid into
Saos-2 cells, and levels of p53 protein were determined
in cell extracts prepared after 48 h by Western blot
analysis. Transfection efficiencies were monitored by
cotransfection of the pJS55-GFP expression plasmid and
determination of the levels of the green fluorescent pro-
tein in the same filter. The in vivo analyses also included
the truncation mutants, M11–M15, that were previously
characterized for their in vitro activities in p53 degrada-
T
Comparison of Biological and Bioc
E6 protein
Colony induction PHK
Positive assaysa No. of coloniesb Inhibitio
E6A 6/6 26–51 1
225/Gly 136 4/6 27/37 81.8 6
229/Gly 103 1/5 5/39 13.7 6
599E/d133–137 2/5 11/34 12.1 6
600E/d128–132 0/4 0/37 62.1 6
601E/d123–127 0/4 0/43 57.8 6
602E/d118–122 1/5 8/38 94.4 6
603E/d111–115 0/4 0/41 57.3 6
1383/d106–110 2/4 19/43 51.0 6
605E/d101–105 3/6 16/37 34.7 6
608E/d78–82 ND N
609E/d73–77 2/4 18/36 21.7 6
a Number of experiments yielding serum- and calcium-resistant colo
b Number of colonies per 10 mg of lipofected E6A DNA plus 10 mg of E
of 37. Average colony number values of the E6 mutant/average colony
c Data are from multiple experiments (4–6). The activity values wer
deviations are given.tion (Sherman et al., 1997). Representative immunoblots
are shown in Fig. 3. The average degradation activities ofthe mutant proteins, relative to E6A, obtained from mul-
tiple independent transfections, were summarized in
Table 1.
Most of the mutants analyzed in these assays showed
similar in vitro and in vivo p53 degradation activities.
However, some mutants that showed no significant ac-
tivity in vivo were still capable of reducing p53 levels in
vitro to a low extent, including mutants 599 (d133–137),
603 (d111–115), 605 (d101–105), and 609 (d73–77). This
could reflect the greater sensitivity of the in vitro assay
due to more efficient p53 ubiquitinization at 25°C as
compared to 37°C (Liu et al., 1999).
Mutants 225 (Gly 136) and 602 (d118–122) exhibited
high p53 degradation activities both in vivo and in vitro,
yet only mutant 225 showed high activity in the calcium–
serum resistance assay. This result clearly indicated that
p53 degradation is not sufficient for the biological func-
tion of E6 in altering the response of PHKs to calcium
and serum. Moreover, mutants 605 (d101–105), 1383
(d106–110), 599 (d133–137), and 609 (d73–77), that dis-
played moderate activities in the biological assay, were
either completely defective (1383) or severely compro-
mised for p53 degradation. This suggests that p53 elim-
ination may not be the critical function required for the
induction of differentiation resistance.
Down regulation of p53 transcriptional activity by HPV
E6 mutants
The physical association of E6 proteins of the “high
risk” HPV types (HPV 16 and HPV 18) with p53 prevents
l Activities of HPV16 E6 Mutants
activation of p53c (percent of control)
E6BP bindingcA Degradation in vitro Degradation in vivo
100 100 100
92.8 6 8.4 94.1 6 12.0 9.4 6 17.4
21.2 6 10.8 17.0 6 13.1 0
36.4 6 13.2 20.3 6 13.9 0
13.0 6 8.8 4.4 6 4.4 0
13.5 6 7.0 18.8 6 5.9 0
89.7 6 10.3 85.8 6 9.0 0
26.2 6 11.4 12.3 6 8.4 0
14.0 6 9.6 7.8 6 6.1 0
24.5 6 12.1 9.5 6 6.6 0
15.7 6 6.0 21.3 6 15.3 0
33.2 6 4.4 13.8 6 11.8 0
PHKs.
ranged between 26 and 51 in the different experiments with an average
r of E6A, both in the same experiments, are given.
lated as percentage of E6A (100%). The average values 6 standardABLE 1
hemica
In
n of T
00
18.1
9.7
11.8
9.3
14.1
15.3
16.5
14.2
15.8
D
14.5
nies in
7 DNA
numbep53 binding to DNA and results in inhibition of p53
transcriptional activity (Crook et al., 1994; Lechner et al.,
313HPV 16 E6 MUTATIONAL ANALYSIS1992; Thomas et al., 1995). In some studies E6 inhibition
of p53 transactivation was shown to be separate from
the ability of E6 to target p53 for degradation (Crook et
al., 1994; Thomas et al., 1995). Recent studies provided
evidence that E6 proteins from the high-risk HPVs pos-
sess an alternative mechanism by which to down regu-
late p53 transcriptional activity, that is, by targeting the
CBP/p300 (Patel et al., 1999; Zimmermann et al., 1999). To
further investigate the correlation between E6 biological
function in calcium–serum resistance and ability to down
regulate p53 transcriptional activity, mutant activities
were evaluated in the above assay.
E6A mutant proteins were cotransfected into NIH/3T3
cells with the p53 expression plasmid (pJS55-p53), the
pG13CAT reporter, and the b-gal expression plasmid, as
previously described (Sherman et al., 1997).
CAT activity was measured in cell extracts prepared
48 h after transfection. Figure 4 shows the results of
FIG. 2. In vitro p53 degradation assays with E6A and series of
epitope-tagged E6 mutants. 35S-labeled p53 and E6 proteins synthe-
sized in RTL and WGE, respectively, were mixed in a standard reaction
and incubated at 25°C. Samples were removed at time 0 and 3 h and
analyzed by SDS–PAGE. Autoradiographs of representative assays are
shown. The levels of p53 were quantified by densitometric scanning
and percentage of p53 degradation was calculated from the ratio
between p53 remaining after 3 h to that of input p53 (time 0). Degra-
dation activity values represent percent of p53 degradation relative to
the degradation obtained with the E6A protein (100%). The average
values of degradation activities from at least four independent experi-
ments with standard deviations are shown in Table 1.representative assays. The overall data were summa-
rized in Table 1.Most of the mutants analyzed showed similar activities
in p53 degradation and inhibition of p53 transactivation.
However, some mutants that displayed minimal or no
activity in p53 degradation were still capable of signifi-
cantly inhibiting p53-dependent TA. These include mu-
tants 600 (d128–132), 601 (d123–127), and 1383 (d106–
110) that were defective for p53 in vivo and in vitro
degradation and mutants 603 (d111–115) that displayed
only minimal activity in the in vitro degradation assays.
Yet, mutants 600, 601, and 603 that exhibited significant
TA inhibitory activity or mutant 602 that displayed high
activity showed no activity or greatly reduced activity in
the biological assay. These results support the hypothe-
sis that inhibition of p53 transcriptional activity alone is
not sufficient for inducing calcium–serum resistance.
This is consistent with our previous data showing that a
dominant mutant human p53 cannot substitute for E6 in
the colony assay (Sherman et al., 1997). Interestingly,
mutants 1383 (d106–110) and 605 (d101–105), which
failed to target p53 for degradation, did exhibit low ac-
tivity for p53 TA inhibition and moderate activity in the
biological assay, suggesting that inhibition of p53 TA may
contribute to E6 biological function in resistance to cal-
cium–serum.
FIG. 3. In vivo p53 degradation assays with E6A and series of
epitope-tagged E6 mutants. Human p53 null Saos-2 cells were
cotransfected with 3 mg p53 expression plasmid, 10 mg E6A/mutant
or vector plasmid, and 2 mg of pJS55-GFP. Cell lysates were pre-
pared after 48 h and equal amounts were separated by SDS–PAGE.
Proteins were detected by Western blot analysis with the indicated
antibodies and quantified by densitometric scanning. Autoradio-
graphs of representative assays are shown. Levels of p53 in the
E6A/mutant transfected cells, normalized relative to GFP, were com-
pared to the levels of p53 in cells transfected with the vector pJS55
and percentage of p53 degradation was determined. Degradation
activity represent the percent of p53 degradation, relative to the
degradation obtained with the E6A plasmid (100%). The average
values from at least four independent experiments with standard
deviations are shown in Table 1.
sfecte
endent
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The significance of E6BP/ERC-55 for E6 function in
serum and calcium resistance was also investigated. We
first examined the effect of E6 on the level of cellular
E6BP expression in PHKs during serum–calcium-in-
duced in vitro differentiation (Fig. 5). Foreskin primary
human keratinocytes were infected with retroviruses en-
coding either E6A or vector DNA. Cells were split, se-
lected in G418, and grown to form monolayers (Alfandari
et al., 1999). The cells were then transferred to differen-
tiation medium containing 2 mM calcium, 10% fetal calf
FIG. 4. Inhibition of p53-mediated transactivation by E6A and series
of p53 expression plasmid, 1 mg of pG13CAT, 10 mg E6A or mutant E6
prepared after 48 h. The percentage of chloramphenicol acetylation
presented as percentage of the control extract activity (100%, cells tran
The average values of the inhibition activities from at least four indepserum, and 1 mg/ml hydrocortisone as previously de-
scribed (Schlegel et al., 1988). Levels of E6BP and in-volucrin, the most abundant precursor of the cornified
envelope and hallmark of squamous epithelial differen-
tiation, were determined by Western blot analysis (Fig. 5).
Upon serum–calcium switch, involucrin was up regu-
lated in both E6A and vector virus-infected cultures and
remained high during the first and second week. There
was no significant changes in E6BP protein expression
as determined by immunoblotting (Chen et al., 1995) in
either E6A or control cultures.
We then assessed the abilities of the above described
mutants as well as previously described E6 truncated
pe-tagged E6 mutants. 3T3/NIH cells were transfected with 3 mg DNA
id, and 1 mg pCMV-b-gal. CAT activity was determined in cell extracts
uantified with a phosphorImager. Inhibition of p53 transactivation is
d with E6A). Autoradiograph of a representative experiment is shown.
experiments with standard deviations are shown in Table 1.of epito
plasm
was qmutants (Sherman and Schlegel, 1996; Sherman et al.,
1997) to associate with E6BP. The E6BP–GST fusion that
315HPV 16 E6 MUTATIONAL ANALYSISencodes the C-terminal 211 amino acids of E6BP (Chen
et al., 1995) was used for binding. Two micrograms of
GST-E6BP and GST proteins, bound to Sepharose beads,
were reacted with equal amounts of the in vitro trans-
lated 35S-labeled E6A/mutant protein. Figure 6 shows the
results of representative assays and Table 1 summarizes
the collated results. As indicated, most of the tested
mutants were severely impaired in E6BP binding. Only
mutant M11 (d141–151) retained substantial binding to
E6BP, with average activity of 74 6 16.4% relative to E6A
(100%). This mutant was previously shown to retain full-
length E6A activity in the calcium–serum resistance as-
say (Sherman and Schlegel, 1996). Mutant 225 (Gly 136)
that showed high activity in the colony assay in PHKs
displayed only inconsistent marginal binding to E6BP,
whereas mutants 599 (d133–137), 1383 (d106–110), 605
(d110–105), and 609 (d73–77) that showed low (599) to
moderate biological activities, were completely defective
in E6BP binding. These results suggest that E6 associ-
ation with E6BP may not be necessary for E6 function in
induction of resistance to calcium- and serum-initiated
differentiation.
DISCUSSION
Resistance to stimuli that induce terminal differentia-
tion of human genital keratinocytes is critical in the
multistep process of cervical carcinogenesis.
The ability to confer resistance to serum- and calcium-
FIG. 5. Western analysis of E6BP and involucrin expression in PHKs
before and after the induction of differentiation by calcium and serum.
Lysates were prepared from PHKs infected with the E6A or vector virus,
before and at different time points (days) after the shift to differentia-
tion-medium. Equal amounts of protein (200 mg) were fractionated and
immunoblotted with the indicated antibodies. Autoradiograms of two
independent experiment are shown.induced terminal differentiation was attributed to the E6
oncoprotein of HPV16 (Sherman and Schlegel, 1996).Previous mutational analyses of HPV16 E6 indicated
that the carboxyl-end region of E6 spanning residues
141–151 is dispensable for this E6 function (Sherman and
Schlegel, 1996). Data provided in the present study point
to the necessity of sequences located upstream from the
extreme end, at the carboxyl-half of E6. Although we
were unable to map a distinct domain required for this
activity, we show that mutations or small deletions within
the putative second zinc-finger region significantly re-
duced E6 ability to generate differentiation-resistant col-
onies in PHKs.
Interestingly, mutations that affected the central por-
tion of the finger were more effective in this respect, as
compared to mutations that affected cysteine residues at
the base of the finger. Mutants 225 (Gly 136), 599 (d133–
137), 1383 (d106–110), and 605 (d101–105) that lack or
substitute the cysteines at positions 136, 106, and 103,
respectively, still retained significant biological activity.
These results imply that sequence-specific requirements,
rather than the finger structure that regulates protein folding
and stability, are important for this E6 function. Mutant
1383, for example, which displayed extremely unstable
phenotype, as deduced from the in vitro translation and
COS cell expression analyses (data not shown), still
exhibited moderate activity in the biological assay.
Defining the mechanisms by which E6 induces resis-
tance to serum and calcium and alters keratinocyte dif-
ferentiation will help in understanding the process of
cervical dysplasia and neoplasia. Previous studies sug-
gested a role for p53 in this E6 function, although the
absolute requirement of p53 was not established (Con-
rad Stoppler et al., 1996; Sherman et al., 1997). Results of
a systematic evaluation of E6 mutants, reported herein,
suggest that E6 ability to induce p53 degradation in vitro
and in vivo, or E6 ability to inhibit p53 transcriptional
activity, may not be the critical activities required for
inducing resistance to serum and calcium. Although we
were unable to detect mutants that lost the capacity to
interact with p53 and still retained full-length E6 level of
activity in the biological assay, we could map mutations
that separated between these activities among mutants
that exhibited partial activities in the respective assays.
For example mutant 602 (d118–122) that displayed high
activity in both p53 degradation and inhibition of p53-
dependent transactivation showed markedly reduced ac-
tivity in the biological assay. Similarly, mutants 600
(d123–132) and 601 (d123–127) that exhibited significant
activity in inhibition of p53 TA were completely defective
in the biological assay. Conversely, mutants 1383 (d106–
110), 605 (d101–105), and 599 (d133–137) that exhibited
only marginal levels of activity in p53 degradation and
low inhibition of p53 TA still retained moderate ability to
induce differentiation-resistant colonies in PHKs. Consis-
tent with previous observations (Sherman et al., 1997),
the data reported herein indicate that inactivation of p53
or even its elimination is not sufficient for the induction of
) Perce
e othe
316 SHERMAN ET AL.resistance to serum and calcium. Moreover, it appears
from this study that p53 inactivation is not a critical
activity required for E6-mediated changes in differentia-
FIG. 6. In vitro association of E6BP with E6A and series of epitope
GST-E6BP fusion proteins were mixed with 35S-labeled in vitro translat
bound products were separated by SDS–PAGE. One microliter of the 35S
protein). The amounts of E6A/mutant proteins added to the beads we
protein bound to E6BP was determined by densitometric scanning of the
E6A protein was 9% (upper gel) or 29% (lower gel) of the added prot
detected with the mutant E6 proteins analyzed in this experiment (0). (B
proteins (10 ml), respectively. No specific binding was detected with thtion. It should be noted, however, that this conclusion is
based on comparison of the activities of the E6 mutantproteins in different assay systems. The possibility still
exists that E6 may have additional mechanisms for re-
ducing p53 levels that could possibly function in PHKs
d E6 mutants. Glutathione-sepharose beads containing 2 mg GST or
eins E6A/mutant in 300 ml LSAB. After 2 h incubation and washes the
d translation product was fractionated separately before binding (input
sted to give approximately equal amounts. Percentage of E6A/mutant
. Representative assays are shown in A and B. (A) Percentage of bound
and 5 ml, respectively). Specific binding, above background, was not
ntage of bound E6A and M11 proteins were 22.7 and 12.5 of the added
r mutants analyzed in this experiment (0).-tagge
ed prot
-labele
re adju
bands
ein (4but not in the reticulocyte lysate based assay or the
transient expression assay in Saos-2 cells. Reduced
317HPV 16 E6 MUTATIONAL ANALYSISlevels of p53 were detected in immortal clones of mam-
mary epithelial cells induced by certain E6 mutants that
lack the ability to degrade p53 in vitro (Liu et al., 1999).
Most of the mutants evaluated in the present study
were previously assessed by others in their intact, non-
tagged, form. In some cases, the results were conflicting
(Crook et al., 1991; Dalal et al., 1996; Foster et al., 1994;
Liu et al., 1999). In the epitope-tagged form, we show that
only mutants 225 (Gly 136) and 602 (d118–122) displayed
high activities in p53 degradation in vivo and in vitro,
consistent with their previously reported in vitro activities
in the intact form (Crook et al., 1991). All other mutants
tested in this study were inactive or showed very low
levels of activity in p53 degradation. The epitope-tagged
mutant proteins displayed, however, similar phenotypes
in the in vitro and in vivo degradation assays, in agree-
ment with previous data on the activities of HPV18 E6
mutants (Gardiol and Banks, 1998).
We show that some of the mutants which were se-
verely impaired for p53 degradation still retained the
capacity to inhibit p53 transcriptional activation, as ex-
emplified by mutants 600 (d128–132), 601 (d123–127),
and 603 (d111–115). This difference can be possibly ex-
plained by recent reports indicating that E6 interacts with
and regulates the function of CBP and p300, cofactors of
p53-dependent transcription. This interaction is indepen-
dent of the ability of E6 to target p53 for degradation
(Patel et al., 1999; Zimmermann et al., 1999). Despite the
capacity of the above mutants to inhibit p53 transcription,
they still failed to alter keratinocyte responses to serum
and calcium.
The significance of the interaction between E6 and E6
BP/ERC-55 for modulating resistance to serum and cal-
cium was also investigated. E6 BP/ERC-55 belongs to a
novel family of multiple EF-hand, low-affinity calcium-
binding proteins that are localized to the secretory path-
way of mammalian cells (for review, see Honore and
Vorum, 2000). The mouse homologue of human ERC-55
specifically associates with the vitamin D receptor (VDR)
(Imai et al., 1997), whose elevation in rat epidermis has
been linked to cell differentiation, and both vitamin D and
calcium appear to contribute to VDR up regulation (Zineb
et al., 1997). The data presented here, however, do not
support a significant role for E6BP/E6 interaction in re-
sistance to serum and calcium. We did not detect major
changes in the expression levels of ERC-55/E6BP protein
in human foreskin keratinocytes that were induced to
differentiate in vitro by serum and calcium. We also
observed no differences in the levels of this protein
between E6-expressing and control keratinocytes. This
is consistent with previous observations indicating sim-
ilar levels of expression of ERC-55 in normal and E6
immortalized human mammary epithelial cells (Chen et
al., 1995) and the inability of E6 to induce E6BP degra-
dation. More important, we mapped mutants that
showed different activities in the colony formation andE6BP binding assays. Of all the mutants analyzed in this
study, only M11 (d141–151) showed efficient binding to
E6BP. This mutant was previously shown to possess
full-length E6 capacity in the colony formation assay
(Sherman and Schlegel, 1996). The rest of the mutants
were unable to bind this protein and had no correlation
to their biological phenotypes. This dissociation is best
exemplified by mutant 225 (Gly 136) that showed high
activity in the colony assays in PHKs, yet showed only
marginal, inconsistent binding activity in the GST-E6BP
binding assays.
The critical target(s) of E6 mediating E6 function in
serum- and calcium-resistance remains to be identified.
In previous study we showed that terminal differentiation
of cultured foreskin keratinocytes, triggered by serum
and calcium, is a progressive process that ends in cell
death with characteristics of apoptosis. E6 expression in
PHKs did not prevent up regulation of squamous differ-
entiation proteins, nor did it prevent the differentiation-
associated growth arrest. E6 expression led, however, to
a significant reduction in cell stratification and cell death
by apoptosis, which correlated with prolonged expres-
sion of Bcl-2 and reduced elevation Bax levels. The data
suggested that E6 inhibits terminal differentiation of fore-
skin PHKs through inhibition of their differentiation-in-
duced apoptotic program (Alfandari et al., 1999). Among
the E6-interacting proteins identified as targets for E6-
mediated degradation, several act in modulation of
apoptosis, promoting cell death in response to different
triggers, including p53, a well-known activator of apopto-
sis (for review, see Vousden, 2000), whose activity was
previously suggested to contribute to keratinocyte differ-
entiation (Weinberg et al., 1995); c-Myc oncogene (Gross-
Mesilaty et al., 1998); and the proapoptotic member of
the Bcl-2 family Bak (Thomas and Banks, 1998, 1999).
Overexpression of c-Myc and Bak was shown to induce
apoptosis (Askew et al., 1991; Evan et al., 1992; Thomas
and Banks, 1998) and both were linked to epidermal cell
differentiation (Gandarillas and Watt, 1997; Krajewski et
al., 1996).
Although we cannot rule out completely the contribu-
tion of p53 in E6 function in serum- and calcium-triggered
differentiation, the data presented herein, and previous
data indicating down regulation of p53 levels during
serum–calcium differentiation and apoptosis of PHKs
(Weinberg et al., 1995; Alfandari et al., 1999), suggest that
there are other important cellular regulators of this re-
sponse. It will be informative to address the relevance of
E6 interactions with other apoptosis-promoting proteins
for mediating resistance to terminal differentiation.
MATERIALS AND METHODS
PlasmidsThe pJS55 expression vectors encoding the epitope-
tagged HPV16 E6 and E6 carboxy-terminal truncation
318 SHERMAN ET AL.mutants were previously described (Sherman and Schle-
gel, 1996).
Epitope-tagged E6 mutants containing small deletions
and point mutations within the carboxy half of E6 (Fig. 1)
were constructed by PCR amplification of the wild-type
E6 mutants, which were a gift from K. Vousden, with
primers containing the Kozak–XhoI sequences in the 59
primer, and the AU1 epitope–HindIII sequences in the 39
primer, as previously described (Sherman and Schlegel,
1996). The resulting fragments were cloned into the XhoI
and HindIII sites of pJS55. All vectors were confirmed by
nucleotide sequence analysis. Expression of the mutant
proteins from the respective vectors was verified by
transfection into COS cells and detection of the proteins
by immunofluorescence and immunoprecipitation with
the AU1 antibody as described previously (Sherman and
Schlegel, 1996). The E6BP cDNA and GST-E6BP vector
were described previously (Chen et al., 1995).
The pJS55-GFP vector was constructed by cloning the
green fluorescence protein (GFP) open reading frame
(ORF) (Chalfie et al., 1994) into the pJS55. The p53 ex-
pression plasmid pJS55-p53 was described previously
(Sherman et al., 1997).
Cell cultures and transfections
Primary human keratinocytes cultured from neonatal
foreskins were grown in keratinocyte SFM (K-SFM) sup-
plemented with 5 ng/ml growth factor (EGF) and 50
mg/ml bovine pituitary extract (BPE) (GIBCO-BRL, Gaith-
ersburg, MD). Kerartinocytes were transfected at pas-
sage two using lipofectin (GIBCO-BRL). Infection of PHKs
with retroviral vectors carrying the E6 gene and selection
in G418 Geneticin were carried out as described previ-
ously (Alfandari et al., 1999). Saos-2 and 3T3/NIH cells
were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal calf serum (FCS).
Cells were transfected by a modified calcium phosphate
procedure as previously described (Sherman and Schle-
gel, 1996).
Induction of colonies resistant to serum/Ca21
differentiation in PHKs
Assays were carried out as described previously
(Schlegel et al., 1988). Briefly, cells were plated at 50%
confluency in 10-cm dishes and transfected (lipofected)
with 10 mg of the E6 test plasmid together with 10 mg of
the E7 expression plasmid. The second day after trans-
fection, cells were plated into 162-cm2 flasks in KSFM
and maintained until cultures became confluent (4–5
days). The medium was then changed to a selection
medium consisting of DMEM (containing 2 mM calcium)
supplemented with 10% FCS and 1 mg/ml hydrocortisone
(Sigma). Cultures were maintained in selection medium
for 3 weeks to allow the formation of serum/Ca21-resis-tant colonies. Controls included cells transfected with
the E7 plasmid or the vector plasmid alone.
p53 degradation assays in vitro and in vivo
In vitro degradation assays with [35S]cysteine–methio-
nine-labeled E6 proteins translated in wheat germ ex-
tract (WGE) and p53 translated in reticulocyte cell lysate
(RTL) were performed in 25°C as described previously
(Sherman et al., 1997).
For the in vivo assays, Saos-2 cells were cotransfected
with 3 mg of the p53 expression plasmid, 10 mg of the E6
test plasmid or vector pJS55, and 2 mg of pJS55-GFP that
was used as a control for transfection efficiency. Cells
were harvested in RIPA buffer after 48 h and the remain-
ing p53 and GFP levels were determined by immunoblot
analysis (described below).
Immunoblotting analysis of protein abundance
Preparation of cell lysates in modified RIPA buffer,
electrophoresis on polyacrylamide gels, and transfer to
nitrocellulose membranes were previously described
(Alfandari et al., 1999). Filters were cut into strips and
reacted with the specific antibodies. Primary antibodies,
the p53 DO-1 monoclonal antibody (Mab) (SC-126) from
Santa Cruz Biotechnology (Santa Cruz, CA); the anti GFP
monoclonal antibody mixture (Cat. No. 1814460) from
Boehringer Mannheim, the human involucrin Mab (19018,
Sigma Israel Chemicals Ltd., Rehovot), the human actin
Mab (1378996, Boehringer Mannheim), and the rabbit
anti-GST-E6BP antiserum (Chen et al., 1995) were used.
Proteins were visualized by enhanced chemilumines-
cence (Amersham, Arlington Heights, IL) using perox-
idose-conjugated anti-mouse IgG (115-035-003, Jackson
ImmunoResearch Laboratories, Inc.) or protein A-perox-
idase (NA9120) (Amersham) according to the manufac-
turer’s instructions. Protein amounts were determined by
densitometric scanning (Dinco and Rhenium Biological
Imaging System BIS 202, Israel).
p53 transactivation assays
Inhibition of p53-dependent transactivation was as-
sessed by transfection of NIH/3T3 mouse cells with 3 mg
of the p53 expression plasmid, 1 mg of the pG13CAT
reporter, 10 mg of each of the E6A/mutant or vector
plasmids, and 1 mg of pCMV-b-galactosidase as a con-
trol for transfection efficiency. CAT assays were carried
out as previously described (Sherman et al., 1997).
E6BP binding assays
In vitro binding to E6BP was tested as described by
Chen et al., 1995. Briefly, 30 ml of the glutathione–Sepha-
rose beads coupled to 2 mg of the GST-E6BP or GST
fusion proteins were incubated in 300 ml LSAB binding
buffer (100 mM NaCl, 100 mM Tris–HCl (pH 8.0), 1%
319HPV 16 E6 MUTATIONAL ANALYSISNP-40, 2 mM dithiothreitol (DTT), 0.1% nonfat dry milk,
and 1 mM phenylmethylsulfonyl fluoride (PMSF)). The
beads were subjected to rotary shaking at 4°C for 30
min, and then comparable amounts of each [35S]cys-
teine–methionine-labeled E6A/mutant protein, translated
in WGE (4–15 ml of the translation product), was added at
equal amounts to the GST and GST-E6BP beads, and
rotation was continued for 2 h at 4°C. After incubation,
the beads were washed four times with LSAB and sub-
jected to SDS–14% polyacrylamide gel electrophoresis.
E6 binding was analyzed by autoradiography. The per-
centage of E6/mutant protein bound to GST-E6 was cal-
culated after subtracting the amount bound to the GST
beads.
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